TSMDA: Target and symptom-based computational model for miRNA-disease-association prediction

by Korawich Uthayopas, Alex G.C. de Sá, Azadeh Alavi, Douglas E.V. Pires, David B. Ascher
Published 2021-12-01

Distinguishing between PTEN clinical phenotypes through mutation analysis

by Stephanie Portelli, Lucy Barr, Alex G.C. de Sá, Douglas E.V. Pires, David B. Ascher
Published 2021-01-01

Structure-guided machine learning prediction of drug resistance mutations in Abelson 1 kinase

by Yunzhuo Zhou, Stephanie Portelli, Megan Pat, Carlos H.M. Rodrigues, Thanh-Binh Nguyen, Douglas E.V. Pires, David B. Ascher
Published 2021-01-01

Unveiling six potent and highly selective antileishmanial agents via the open source compound collection ‘Pathogen Box’ against antimony-sensitive and -resistant Leishmania brazili...

by Juliano A. Souza Silva, Luiza G. Tunes, Roney S. Coimbra, David B. Ascher, Douglas E.V. Pires, Rubens L. Monte-Neto
Published 2021-01-01

The Presence, Persistence and Functional Properties of Plasmodium vivax Duffy Binding Protein II Antibodies Are Influenced by HLA Class II Allelic Variants.

by Flora S Kano, Flávia A Souza-Silva, Leticia M Torres, Barbara A S Lima, Taís N Sousa, Jéssica R S Alves, Roberto S Rocha, Cor J F Fontes, Bruno A M Sanchez, John H Adams, Cristiana F A Brito, Douglas E V Pires, David B Ascher, Ana Maria Sell, Luzia H Carvalho
Published 2016-12-01

Familial STAG2 germline mutation defines a new human cohesinopathy

by Fernanda C. Soardi, Alice Machado-Silva, Natália D. Linhares, Ge Zheng, Qianhui Qu, Heloísa B. Pena, Thaís M. M. Martins, Helaine G. S. Vieira, Núbia B. Pereira, Raquel C. Melo-Minardi, Carolina C. Gomes, Ricardo S. Gomez, Dawidson A. Gomes, Douglas E. V. Pires, David B. Ascher, Hongtao Yu, Sérgio D. J. Pena
Published 2017-03-01